GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (NYSE:JNJ) » Definitions » Forward Rate of Return (Yacktman) %

Johnson & Johnson (Johnson & Johnson) Forward Rate of Return (Yacktman) %

: 4.25% (As of Dec. 2023)
View and export this data going back to 1944. Start your Free Trial

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Johnson & Johnson's forward rate of return for was 4.25%.

The historical rank and industry rank for Johnson & Johnson's Forward Rate of Return (Yacktman) % or its related term are showing as below:

JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.94   Med: 7.05   Max: 14.35
Current: 4.59

During the past 13 years, Johnson & Johnson's highest Forward Rate of Return was 14.35. The lowest was 1.94. And the median was 7.05.

JNJ's Forward Rate of Return (Yacktman) % is ranked worse than
59.61% of 619 companies
in the Drug Manufacturers industry
Industry Median: 8.52 vs JNJ: 4.59

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Johnson & Johnson Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Johnson & Johnson's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 6.87 6.46 5.58 4.25

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Forward Rate of Return (Yacktman) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.85 4.01 4.14 4.25 -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Forward Rate of Return (Yacktman) % Distribution

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Forward Rate of Return (Yacktman) % falls into.



Johnson & Johnson Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Johnson & Johnson's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=6.83238095/158.19+0.0082
=5.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Johnson & Johnson  (NYSE:JNJ) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Johnson & Johnson Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson (Johnson & Johnson) Business Description

Industry
Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Executives
Timothy Schmid officer: EVP, WW Chair, MedTech ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
William Hait officer: See Remarks ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Peter Fasolo officer: VP, Worldwide Human Resources JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Kathryn E Wengel officer: EVP, Chief GSC Officer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
John C Reed officer: EVP, Pharmaceuticals R&D ONE JOHNSON & JOHNSON PLAZA, WHQ 2134, NEW BRUNSWICK NJ 08933
James D. Swanson officer: EVP, Chief Information Officer ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Paula A Johnson director 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph J Wolk officer: Exec VP, CFO JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Ashley Mcevoy officer: EVP, WW Chair, Medical Devices JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jennifer L Taubert officer: EVP, WW Chair, Pharmaceuticals JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Robert J Decker officer: Controller, CAO ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Thibaut Mongon officer: Exec VP, WW Chair, Consumer JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Elizabeth Forminard officer: Executive VP, General Counsel ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Darius Adamczyk director 855 S. MINT STREET, CHARLOTTE NC 28202
Vanessa Broadhurst officer: EVP, Global Corp Aff. ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933